Tagged with OP

Switzerland Dr Nicolas Fischer introduces Light Chain Bioscience, a Swiss biotech company focusing on the discovery and development of bispecific antibodies using proprietary technology. Fischer also outlines the competitiveness of Light Chain’s platform, the company’s partnership strategy, and his goals for future growth.   There is no question that bispecific and…

Switzerland Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva outlines his motivations behind taking on this new challenge, how the company’s approach to oncology treatment differs from  – and…

China Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into rare disease public insurance coverage across key cities in China.   On May 30, 2020, the China Organization for Rare Disorders (CORD) and the management consulting team…

USA PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower US patients’ out-of-pocket spending and continue to drive innovation.   By bringing an end to the pandemic and lowering out-of-pocket…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Germany After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into public opinion on healthcare   STADA, based in Bad Vilbel, focuses on a two-pillar strategy consisting of generics, including specialty…

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

Global Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19 vaccines from bench to market in less than a year and introduces the IFPMA’s new #TeamVaccines campaign, shedding light on the personal stories behind this miraculous effort.   The story of COVID-19…

Europe Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit, with the UK diverging from the rest of the continent in regulatory terms and the launch of the European Commission’s Pharmaceutical Strategy for Europe.   After four…

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

Switzerland Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs. Although its approval times are increasing, raising doubts about Swissmedic’s continued place at the top table of global regulators, initiatives…

Europe With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key trends and developments as well as profiling the most innovative global players in this space. We start the party off with five of the most promising clinical-stage biotech companies…